{"id":35266,"date":"2025-06-16T15:21:34","date_gmt":"2025-06-16T07:21:34","guid":{"rendered":"https:\/\/flcube.com\/?p=35266"},"modified":"2025-06-16T15:21:35","modified_gmt":"2025-06-16T07:21:35","slug":"xuanzhu-biopharma-files-for-hong-kong-ipo-to-advance-innovative-drug-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35266","title":{"rendered":"Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline"},"content":{"rendered":"\n<p>Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China&#8217;s Sihuan Pharmaceutical Holdings Group Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/0460:HKG\">HKG: 0460<\/a>), has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) acting as the sole sponsor. This strategic move aims to secure funding for the advancement of its innovative therapies in gastrointestinal disorders, oncology, and non-alcoholic steatohepatitis (NASH).<\/p>\n\n\n\n<p><strong>Core Products and Development Pipeline<\/strong><br>Xuanzhu Biopharmaceutical has three core products that have reached the New Drug Application (NDA) stage. These include KBP-3571, a proton pump inhibitor approved for duodenal ulcer treatment and commercialized since November 2023; XZP-3287, a CDK4\/6 inhibitor with two NDAs approved for HR+\/HER2- advanced breast cancer and an additional NDA filing accepted in May 2025; and XZP-3621, an ALK inhibitor for ALK+ NSCLC, currently under development as a postoperative adjuvant therapy.<\/p>\n\n\n\n<p><strong>Early-Stage Oncology Assets<\/strong><br>The company also boasts four key oncology assets: KM602, KM501, XZP-7797, and XZP-6924, all at Phase I\/IND stages. Its NASH pipeline includes XZP-5610 and XZP-6019, which are at Phase I and IND stages, respectively.<\/p>\n\n\n\n<p><strong>IPO Proceeds and Strategic Focus<\/strong><br>The net proceeds from the IPO will be dedicated to advancing Xuanzhu Biopharmaceutical&#8217;s pipeline development and supporting commercialization efforts. This funding will further solidify the company&#8217;s position in the biopharmaceutical sector, enabling it to continue its innovative research and expand its market presence.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/sehk25061301829_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk25061301829_c.\"><\/object><a id=\"wp-block-file--media-40b15c1e-697b-4bc5-9aa3-d8087e25ea8a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/sehk25061301829_c.pdf\">sehk25061301829_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/sehk25061301829_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-40b15c1e-697b-4bc5-9aa3-d8087e25ea8a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China&#8217;s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460),&#8230;<\/p>\n","protected":false},"author":1,"featured_media":35268,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,930,72,146,670],"class_list":["post-35266","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-hkg-0460","tag-ipo","tag-sihuan-pharmaceutical","tag-xuanzhu-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China&#039;s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) acting as the sole sponsor. This strategic move aims to secure funding for the advancement of its innovative therapies in gastrointestinal disorders, oncology, and non-alcoholic steatohepatitis (NASH).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35266\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline\" \/>\n<meta property=\"og:description\" content=\"Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China&#039;s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) acting as the sole sponsor. This strategic move aims to secure funding for the advancement of its innovative therapies in gastrointestinal disorders, oncology, and non-alcoholic steatohepatitis (NASH).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35266\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T07:21:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-16T07:21:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1611.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35266#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35266\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline\",\"datePublished\":\"2025-06-16T07:21:34+00:00\",\"dateModified\":\"2025-06-16T07:21:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35266\"},\"wordCount\":244,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35266#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1611.webp\",\"keywords\":[\"Cancer\",\"HKG: 0460\",\"IPO\",\"Sihuan Pharmaceutical\",\"Xuanzhu Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35266#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35266\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35266\",\"name\":\"Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35266#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35266#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1611.webp\",\"datePublished\":\"2025-06-16T07:21:34+00:00\",\"dateModified\":\"2025-06-16T07:21:35+00:00\",\"description\":\"Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China's Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) acting as the sole sponsor. This strategic move aims to secure funding for the advancement of its innovative therapies in gastrointestinal disorders, oncology, and non-alcoholic steatohepatitis (NASH).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35266#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35266\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35266#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1611.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1611.webp\",\"width\":1080,\"height\":608,\"caption\":\"Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35266#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China's Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) acting as the sole sponsor. This strategic move aims to secure funding for the advancement of its innovative therapies in gastrointestinal disorders, oncology, and non-alcoholic steatohepatitis (NASH).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35266","og_locale":"en_US","og_type":"article","og_title":"Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline","og_description":"Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China's Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) acting as the sole sponsor. This strategic move aims to secure funding for the advancement of its innovative therapies in gastrointestinal disorders, oncology, and non-alcoholic steatohepatitis (NASH).","og_url":"https:\/\/flcube.com\/?p=35266","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-16T07:21:34+00:00","article_modified_time":"2025-06-16T07:21:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1611.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35266#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35266"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline","datePublished":"2025-06-16T07:21:34+00:00","dateModified":"2025-06-16T07:21:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35266"},"wordCount":244,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35266#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1611.webp","keywords":["Cancer","HKG: 0460","IPO","Sihuan Pharmaceutical","Xuanzhu Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35266#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35266","url":"https:\/\/flcube.com\/?p=35266","name":"Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35266#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35266#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1611.webp","datePublished":"2025-06-16T07:21:34+00:00","dateModified":"2025-06-16T07:21:35+00:00","description":"Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China's Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) acting as the sole sponsor. This strategic move aims to secure funding for the advancement of its innovative therapies in gastrointestinal disorders, oncology, and non-alcoholic steatohepatitis (NASH).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35266#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35266"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35266#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1611.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1611.webp","width":1080,"height":608,"caption":"Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35266#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1611.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35266"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35266\/revisions"}],"predecessor-version":[{"id":35269,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35266\/revisions\/35269"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35268"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}